Accessibility

Our global life sciences company brings diagnostic testing & drug development together.

Labcorp.com

Clinical Use of Vectra Cardiovascular Risk

Vectra Cardiovascular Risk incorporates a personalized assessment of inflammation to predict a rheumatoid arthritis (RA) patient’s risk for a cardiovascular event in the next 3 years.

Vectra Cardiovascular Risk provides an actionable result at point of care that highlights the role of reducing systemic inflammation associated with RA.

Patients with RA have approximately 50% greater risk for cardiovascular disease compared to the general population.1

30% of cardiovascular risk in patients with RA is attributed to systemic inflammation and other RA related factors.2

Traditional cardiovascular (CV) risk factors do not fully explain the increased CV risk seen in RA patients.3

Doctor With Patient

The Science of Vectra Cardiovascular Risk

  • Vectra Cardiovascular Risk incorporates the patient’s Vectra Score, 3 blood biomarkers, age, history of diabetes, hypertension, cardiovascular disease, and tobacco use.
  • Vectra Cardiovascular Risk has been developed and validated utilizing over 30,000 Medicare patients with rheumatoid arthritis (RA).
  • Vectra Cardiovascular Risk has been externally validated in a younger independent cohort whose median age was 54.
  • Vectra Cardiovascular Risk is unique because it incorporates personalized multi-biomarker-based assessment of RA inflammation to predict a patient’s cardiovascular risk.
  • Vectra Cardiovascular Risk accurately predicts cardiovascular events in patients with low, moderate, or high Vectra Scores.

Vectra Cardiovascular Risk (MBDA-based CVD Risk Predictor) and Vectra Clinical Data

Derivation and Internal Validation of a Multi-Biomarker-Based Cardiovascular Disease Risk Prediction Score for Rheumatoid Arthritis Patients

Cardiovascular disease (CVD) is the leading cause of mortality for patients with rheumatoid arthritis (RA), accounting for 30 – 40% of deaths. Patients with RA have approximately 50% greater risk for CVD compared to the general population. Accurate CVD risk prediction could improve care for RA patients. The MBDA-based CVD risk prediction score (Vectra Cardiovascular Risk) provides rheumatologists with a tool for assessing CVD risk to inform the management of traditional CVD risk factors and RA inflammation.3

External Validation of Multi-Biomarker-Based Cardiovascular Disease Risk Prediction Score for Rheumatoid Arthritis Patients

Vectra Cardiovascular Risk was validated in a cohort younger than, and independent of, the Medicare cohort originally used for test development.

Performance of the MBDA-based CVD Risk Score in RA Patient Groups of Clinical Interest

The Vectra Cardiovascular Risk score predicts risk for myocardial infarction (MI), stroke, or fatal CVD in the next three years for rheumatoid arthritis patients and has been internally validated. Goodness of fit analyses indicated good accuracy overall, and in subgroups based on level of Vectra Score, sex, and statin use.

Biomarker-Related Risk for Myocardial Infarction and Serious Infections in Patients with Rheumatoid Arthritis

High Vectra Scores are associated with an increased risk of hospitalized infection, myocardial infarction (MI) and coronary heart disease (CHD).

Test Reports: A Personalized Precision Tool 

The Vectra Report gives a molecular assessment of RA disease. Vectra demonstrates its unsurpassed ability to predict radiographic progression as a personalized inflammatory measure for patients with RA. Vectra is a validated, advanced blood test performed by a CLIA-certified laboratory.

See sample report (coming soon)

The Provider Guide

Download the brochure to learn more about Vectra and how it can help to improve patient and provider decisions.

References

  1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-7.
  2. Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel P, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48-54. 3. Crowson CS, Rollefstad S, Ikdahl E, Kitas GD, van Riel P, Gabriel SE, et al. Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2018;77(1):48-54. 
  3. Curtis, J.R., Xie, F., Crown, C.S. et al. Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients. Arthritis Res Ther 22, 282 (2020) https://doi.org/10.1186/s13075-020-02355-0.